Novel enzyme therapy will treat adults with PKU who have uncontrolled blood phenylalanine concentrations with current treatment. The US Food and Drug Administration (FDA) has approved biotech ...

“Based on the programme’s progress and data to date, we had expected the study to demonstrate the potential for SYNB1934 to provide an important new treatment option for those affected by PKU.” ...

NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the <a ta ...

The patents, based on these new findings, cover additional claims for Relief’s investigational drug RLF-OD032, a highly concentrated, novel liquid formulation of sapropterin dihydrochloride, for the ...

Sami Corwin has given his Buy rating due to a combination of factors that indicate strong potential for PTC Therapeutics’ lead candidate, sepiapterin, in treating phenylketonuria (PKU).

New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2024 /RELIEF ...

GENEVA, SWITZARLAND / ACCESSWIRE / October 29, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...